R&D
Parkinson’s disease: Transitioning from symptom control to d...
The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
Patients
Rewriting the MASLD playbook
Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.
Digital
Sponsored
Solution Spotlight: InsightBrain – AI-powered precision inte...
InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition.
Patients
Every drug is a story, with Thomas Goetz
Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.
R&D
From genetic insight to Phase 3: What rare neurology require...
Rare neurology is not defined by a lack of scientific opportunity or capital.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
